Sarepta Therapeutics (SRPT) Cash from Operations (2010 - 2026)

Sarepta Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 202683000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 65.26% year-over-year to 202683000.0 in Q1 2026; TTM through Mar 2026 was 175275000.0, a 132.03% increase from a year earlier, with the FY2025 full-year figure at 205479000.0, changed 0.15% from the prior year.
• Cash from Operations retreated to 202683000.0 in Q1 2026 per SRPT's latest filing, from 131206000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 261337000.0 in Q2 2025 and bottomed at 583437000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 70699000.0 (2024), against an average of 84722823.53.
• Across the five-year window, Cash from Operations plunged 215.05% in 2022 and surged 1649.01% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 92392000.0 in 2022, then surged by 40.84% to 54657000.0 in 2023, then jumped by 268.41% to 92046000.0 in 2024, then soared by 42.54% to 131206000.0 in 2025, then tumbled by 254.48% to 202683000.0 in 2026.
• Per Business Quant, the three latest SRPT Cash from Operations figures stand at 202683000.0 (Q1 2026), 131206000.0 (Q4 2025), and 14585000.0 (Q3 2025).